Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium –Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus
ConclusionsEmpirical models established based on the effect of UGE well predicted the renal function-dependent long-term glucose-lowering effects of ipragliflozin in patients with T2DM.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | SGLT2 Inhibitors | Sodium | Study | Urology & Nephrology